Skip to main content

Primary Care Physician Use of Counterpart Assistant Technology Associated with Better Health Outcomes in Patients with Congestive Heart Failure

New whitepaper highlights how a relationship with a Primary Care Physician (“PCP”) that uses Counterpart Assistant is associated with better clinical management, and fewer hospitalizations (18% lower) and readmissions (25% lower) in heart failure patients

WILMINGTON, Del., May 01, 2025 (GLOBE NEWSWIRE) — Counterpart Health, Inc. (“Counterpart”), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) and a leading AI-powered physician-enablement platform, today released research demonstrating how Counterpart Assistant (“CA”) use is associated with better management of congestive heart failure (“CHF”). The analysis, titled “Driving Clinical Excellence in Chronic Disease: Counterpart Assistant’s Role in Heart Failure Care,” details the significant positive association among CHF patients between better clinical care and lower hospitalizations, and having a relationship with a PCP that uses Counterpart Assistant.

Key highlights of the study include:

  • A relationship with a CA provider was associated with better outcomes, including a lower average number of all-cause hospitalizations (18% lower) and 30-day readmissions (25% lower) for CHF patients enrolled in Clover Health’s Medicare Advantage (MA) plans.
  • CA provides actionable insights at the point of care, which supports earlier detection of chronic disease, tracking of disease progression and severity, and guideline-based treatment.
  • A relationship with a PCP who uses CA was associated with better clinical care for patients with CHF, including higher rates of outpatient cardiologist visits and in-home care management.

“At Counterpart Health, we are committed to developing technology solutions that truly augment the capabilities of our healthcare providers,” stated Dr. David Tsay MD, PhD, Chief Medical Officer of Counterpart Health and co-author of the whitepaper. “The results of this study on Counterpart Assistant and congestive heart failure demonstrate how providing clinicians with timely, data-driven insights can help lead to significant improvements in patient outcomes. This technology is designed to be a collaborative partner, empowering them to deliver even more effective and personalized care.”

CA has empowered providers in patient care by focusing on clinical excellence in chronic disease detection and management, emphasizing proactive interventions and longitudinal care. Congestive heart failure in particular is a prevalent and potentially debilitating chronic condition that poses a substantial burden on patients in the Medicare population. According to CMS, heart failure is the leading cause of hospitalizations among older adults, and Medicare enrollees with heart failure have the highest readmission rate of any condition.

“For value-based care to truly succeed, we must prioritize proactive and effective management of chronic diseases,” said Conrad Wai, CEO of Counterpart Health. “Counterpart Assistant is a testament to this commitment, offering clinicians actionable intelligence that can translate to improved care for patients with heart failure and a significant decrease in costly acute episodes. This technology demonstrates that enhanced clinical quality and reduced cost of care delivery are not mutually exclusive, but rather, achievable through intelligent physician enablement.”

This is the fourth retrospective data analysis conducted by the Company to measure the clinical impact of CA on the identification and management of chronic diseases. The previous analyses focus on the earlier diagnosis and treatment of Diabetes and Chronic Kidney Disease, and the technology’s impact on Medication Adherence.

To learn more about Counterpart Health, visit: www.counterparthealth.com.

About Counterpart Health
Counterpart Health, a subsidiary of Clover Health Investments, Corp., or Clover Health, is a leading AI powered physician enablement platform. Counterpart Health’s flagship software platform, Counterpart Assistant, was incubated by Clover Health as Clover Assistant and has helped improve plan performance and clinical outcomes for Medicare members through proprietary AI technology. Counterpart Health extends the benefits of the data-driven technology platform outside of Clover Health’s Medicare Advantage plan to a wider audience, to enable enhanced patient outcomes and reduced healthcare costs nationwide. Clover Health has published data demonstrating the technology’s impact on Medication Adherence, as well as the earlier identification and management of Diabetes and Chronic Kidney Disease.

Investor Relations:
Ryan Schmidt
investors@cloverhealth.com

Press Inquiries:
press@cloverhealth.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.